UNITED
STATES
 SECURITIES
AND EXCHANGE COMMISSION
 Washington,
D.C. 20549
 
 FORM
10-Q/A
 (Amendment
No. 1)
 (Mark
One)
 
 x
              QUARTERLY REPORT PURSUANT TO
      SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
      1934
 
 For the quarterly period ended June 30,
2009
 
 or
 
  ̈
              TRANSITION REPORT PURSUANT TO
      SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
      1934
 
 For the transition period from
____________ to ____________
 
 Commission
file number:  001-15281
 
 REPROS
THERAPEUTICS INC.
 (Exact
Name of Registrant as Specified in its Charter)
 
 Delaware
                
                2408
      Timberloch Place, Suite B-7
                
                76-0233274(State
      or other jurisdiction of
                
                The
      Woodlands, Texas 77380
                
                (IRS
      Employerincorporation
      or organization)
                
                (Address
      of principal executive offices
                  and
      zip code)
                
                Identification
      No.)
 
 (281)
      719-3400(Registrant's
      telephone number,
                  including
      area code)
 
 
 Indicate by check mark whether the
registrant (1) has filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and
(2) has been subject to such filing requirements for the past 90
days.    YesxNo ̈
 
 Indicate by check mark whether the
registrant has submitted electronically and posted on its corporate Web site, if
any, every Interactive Data File required to be submitted and posted pursuant to
Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such
files).    Yes  ̈    No   ̈
 
 Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a non-accelerated
filer or smaller reporting company.  See definition of "accelerated
filer", "large accelerated filer" and "smaller reporting company" in Rule 12b-2
of the Exchange Act. (Check one):
 
 Large
accelerated filer  ̈  Accelerated
filer x  Non-accelerated
filer  ̈   Smaller
reporting company    ̈
 
 Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of theExchange
Act).Yes ̈No   x
 
 As of August 14, 2009, there were
outstanding 15,177,404 sharesof Common Stock, par
value $.001 per share, of the Registrant.
  
  Explanatory
Note
 
 This
Amendment No. 1 to the Repros Therapeutics Inc. Quarterly Report on Form 10-Q
for the quarter ended June 30, 2009 is being filed for the sole purpose of
correcting the title in the signature line of Louis Ploth, Jr. on the signature
page.  No other changes are being made.
  2
  SIGNATURES
 
 In
accordance with the requirements of the Exchange Act, the registrant caused this
report to be signed on its behalf by the undersigned, thereunto duly
authorized.
 
 REPROS
      THERAPEUTICS INC.Date:  August
      18, 2009By:
                  /s/ Joseph S. PodolskiJoseph S. PodolskiChief Executive Officer and Director(Principal Executive Officer)Date:  August
      18, 2009By:
                  /s/ Louis Ploth, Jr.Louis Ploth, Jr.Chief Financial Officer and Secretary(Principal Financial and Accounting
Officer)
  3